Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$37 Mln
Revenue (TTM)
$258 Mln
Net Profit (TTM)
$16 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
3.4
P/B Ratio
0.1
Industry P/E
28.02
EV/EBITDA
1.7
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$--
EPS
$1.2
Face value
--
Shares outstanding
12,958,200
CFO
$319.47 Mln
EBITDA
$282.48 Mln
Net Profit
$197.16 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eagle Pharmaceuticals (EGRX)
| -- | 55.0 | -- | -32.6 | -59.8 | -43.4 | -29.3 |
|
BSE Sensex*
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Eagle Pharmaceuticals (EGRX)
| -82.1 | -42.6 | 9.3 | -22.5 | 49.1 | -24.5 | -32.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eagle Pharmaceuticals (EGRX)
|
2.8 | 37.3 | 257.6 | 15.6 | 14.3 | -83.4 | 3.4 | 0.1 |
| 17.9 | 4,328.3 | 459.4 | 206.8 | 25.6 | 68.3 | 21.6 | 11.3 | |
| 7.9 | 3,640.5 | 2,830.2 | -13.1 | 11.5 | -- | -- | 86.1 | |
| 101.7 | 4,957.6 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 93.2 | |
| 54.1 | 10,547.7 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.4 | 1.8 | |
| 42.2 | 7,923.7 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 74.3 | 7,569.5 | 685.5 | 132.9 | 15.6 | 20.1 | 62.1 | 11.1 | |
| 13.4 | 6,684.9 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.9 | 1.1 | |
| 84.4 | 4,123.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.4 | 2.2 | |
| 8.9 | 10,410.5 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers... Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Address: 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677 Read more
Interim Principal Executive Officer & Executive Chairman of the Board
Mr. Michael Graves
Interim Principal Executive Officer & Executive Chairman of the Board
Mr. Michael Graves
Headquarters
Woodcliff Lake, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Eagle Pharmaceuticals Inc (EGRX) stood at $ 491 Mln as on 30-Jun-23
The share price of Eagle Pharmaceuticals Inc (EGRX) is $2.79 (NASDAQ) as of 23-Jun-2025 14:21 EDT. Eagle Pharmaceuticals Inc (EGRX) has given a return of -59.76% in the last 3 years.
Eagle Pharmaceuticals Inc (EGRX) has a market capitalisation of $ 37 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Eagle Pharmaceuticals Inc (EGRX) is 0.15 times as on 23-Jun-2025, a 97% discount to its peers’ median range of 4.74 times.
The P/E ratio of Eagle Pharmaceuticals Inc (EGRX) is 3.38 times as on 23-Jun-2025, a 88% discount to its peers’ median range of 28.02 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Eagle Pharmaceuticals Inc (EGRX) and enter the required number of quantities and click on buy to purchase the shares of Eagle Pharmaceuticals Inc (EGRX).
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Address: 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677
The CEO & director of Mr. Michael Graves. is Eagle Pharmaceuticals Inc (EGRX), and CFO & Sr. VP is Mr. Michael Graves.
There is no promoter pledging in Eagle Pharmaceuticals Inc (EGRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,059
|
|
|
1,029
|
|
|
762
|
|
|
761
|
|
|
676
|
|
|
507
|
|
|
433
|
|
|
414
|
|
|
368
|
| Eagle Pharmaceuticals Inc. (EGRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-83.45
|
|
Operating margin(%)
|
14.26
|
|
Net Margin(%)
|
6.18
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Eagle Pharmaceuticals Inc (EGRX) was $16 Mln.
$-0.09
(
